HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NBTX
Nanobiotix S.A.
There isn't enough reported data to score NBTX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NBTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
NBTX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NBTX PE Valuation
NBTX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NBTX Forward outlook
There aren't enough analyst estimates for NBTX to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NBTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2024 | -$0.82 | +$1.05 |
| Q4 2023 | -$1.20 | +$0.62 |
| Q2 2023 | -$1.87 | -$0.50 |
| Q4 2022 | -$1.82 | -$0.32 |
NBTX has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NBTX in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over NBTX on profitability, with a higher operating margin.
NBTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $6.2M | -79% |
| Q2 2025 | $29.6M | +187% |
| Q2 2024 | $10.3M | +182% |
| Q4 2023 | $36.6M | +855% |
| Q2 2023 | $3.7M | +148% |
| Q4 2022 | $3.8M | +160% |
| Q2 2022 | $1.5M | +0.8% |
| Q4 2021 | $1.5M | +51% |
NBTX's revenue has slid since its 2023 peak: $6M last quarter, down 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -323% | -68 points |
| Q4 2025 | -195% | -191 points |
| Q2 2025 | 3% | +773 points |
| Q2 2024 | -255% | +1693 points |
| Q4 2023 | -4.3% | +1713 points |
| Q2 2023 | -770% | +1487 points |
| Q4 2022 | -604% | +1453 points |
| Q2 2022 | -1947% | -678 points |
NBTX's operating margin was −323% last quarter, down 319 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
NBTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$25.5M | -$6M |
| Q4 2025 | -$18.2M | -$2.6M |
| Q2 2025 | -$19.5M | -$12.5M |
| Q4 2024 | -$15.6M | -394% |
| Q2 2024 | -$7M | +$12.5M |
| Q4 2023 | $5.3M | +$27.1M |
| Q2 2023 | -$19.5M | -$1.1K |
| Q4 2022 | -$21.8M | -$5.1M |
NBTX has burned cash in almost every quarter: −$79M over the past year, against −$43M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NBTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NBTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.1% | +1.5M shares |
| 1 year | +116% | +26.3M shares |
| 3 years | +227% | +33.9M shares |
NBTX has 49M diluted shares, up 116% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2024 | — |
| Q4 2020 | — |
| Q2 2020 | — |
| Q4 2019 | — |
| Q2 2019 | — |
| Q4 2018 | — |
| Q2 2018 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NBTX Net Leverage
NBTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NBTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.4 | Neutral |
| Stochastic | 41.2 | Neutral |
NBTX's weekly RSI is 49 (neutral) and its Stochastic is 41 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NBTX PE vs Healthcare Sector
NBTX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NBTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.5 | 13% above |
| 20 week MA | $34.6 | 6.8% below |
| 50 week MA | $32.0 | 0.7% above |
| 100 week MA | $20.0 | 61% above |
| 200 week MA | $12.9 | 150% above |
NBTX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
NBTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $17.0 | $17.2 | +1.5% |
| 2021 | $17.2 | $7.87 | -54% |
| 2022 | $7.87 | $4.00 | -49% |
| 2023 | $4.00 | $7.28 | +82% |
| 2024 | $7.28 | $3.00 | -59% |
| 2025 | $3.00 | $23.0 | +668% |
| 2026 YTD | $23.0 | $32.3 | +40% |
NBTX has the edge over HIMS on returns for 2026, with the stronger performance.